Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE versus HYPAQUE 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE versus HYPAQUE 76.
HYPAQUE vs HYPAQUE-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hypaque (diatrizoate sodium/diatrizoate meglumine) is an ionic, high-osmolar iodinated contrast agent. It attenuates X-rays by increasing the atomic density in tissues, providing radiographic contrast. It is not pharmacologically active but may cause physiological effects due to hyperosmolality.
HYPAQUE-76 (diatrizoate meglumine and diatrizoate sodium) is an ionic iodinated contrast agent that attenuates X-rays, providing radiographic contrast. Its mechanism involves high iodine content (76%) that absorbs X-rays, distinguishing anatomical structures in imaging procedures.
Intravenous: 50-300 mL of 30-60% solution depending on procedure; maximum 5 mL/kg. Intra-arterial: 5-80 mL per injection. Intrathecal: Not recommended due to neurotoxicity.
Intravenous: 50-100 mL (as a 76% solution, 370 mg iodine/mL) for contrast imaging, administered as a bolus or infusion; maximum 300 mL per procedure.
None Documented
None Documented
The terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. In renal impairment, half-life is prolonged and may exceed 20 hours in severe cases, requiring dose adjustment.
Terminal elimination half-life of 1.5-2 hours in normal renal function. Prolonged to >10 hours in moderate renal impairment (CrCl 30-50 mL/min). Closely correlates with creatinine clearance.
The drug is excreted unchanged primarily by the kidneys via glomerular filtration. Renal excretion accounts for >95% of elimination; biliary/fecal excretion is negligible (<5%).
Primarily renal; >95% excreted unchanged in urine within 24 hours via glomerular filtration. Fecal excretion minimal (<5%). Biliary excretion negligible.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent